Product Description
Febuxostat is used to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol. This medicine is a xanthine oxidase inhibitor. It works by causing less uric acid to be produced by the body. (Sourced from: https://www.mayoclinic.org/drugs-supplements/febuxostat-oral-route/side-effects/drg-20074780?p=1)
Mechanisms of Action: XO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: Gout
Known Adverse Events: Arthralgia
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Gout
Phase 1: Healthy Volunteers|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HR091506-301 | P3 |
Not yet recruiting |
Gout |
2026-06-01 |
34% |
| HR091506-301 | P3 |
Not yet recruiting |
Gout |
2026-06-01 |
34% |
| HR091506-302 | P3 |
Not yet recruiting |
Gout |
2024-11-01 |
34% |
| HR091506-302 | P3 |
Not yet recruiting |
Gout |
2024-11-01 |
34% |
| FEB-031-23 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-10-01 |
|
| FYU-981-J086-301 | P3 |
Completed |
Gout |
2023-06-14 |
34% |
| FYU-981-J086-301 | P3 |
Completed |
Gout |
2023-06-14 |
34% |